The Cognitive Effects of 'Brainwaves' Supplementation in Cognitively Intact Older Adults

Cognitive Change Clinical Trial

Official title:

The Cognitive Effects of 'Brainwaves' Supplementation in Cognitively Intact Older Adults Experiencing Subjective Memory Decline: A Randomized, Placebo Controlled, Parallel Groups Investigation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05504668
• Other study ID #: 50BP1
• Status: Completed
• Phase: N/A
• Start date: August 20, 2019
• Est. completion date: February 2, 2022

Study information

• Verified date: August 2022
• Source: Northumbria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigated the effects of a proprietorial herbal supplement, Turmeric Brainwave (now Mind focus), on cognition, mood and the microbiome in older adults experiencing subjective memory decline, following 90 days supplementation.

Description:

The primary aim of this randomised, double blind, placebo-controlled, parallel groups study was to assess the effects of a daily dose of Turmeric Brainwaves, versus placebo, both acutely and following 90 days consumption. Effects were to be assessed in 55-75 year old males and females who reported that their memory now was worse than when in their 20's. Effects were assessed via cognitive (including COMPASS and Cognimapp as well as 2 real-world long-term memory tasks (location-action (AKA Prospective Remembering Video Procedure (PRVP)) and recall of facts)) and mood (using visual analogue scales) outcomes and, additionally, stool and urine samples collected at the beginning and the end of the trial period assessed the microfloral community of the gut and urinary metabolome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 174
• Est. completion date: February 2, 2022
• Est. primary completion date: February 2, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years to 75 Years

Eligibility

Inclusion Criteria:

• 55-75 years at time of enrolment

• Answers yes to the question 'would you say that your memory now is worse now than it used to be in your 20's?'

Exclusion Criteria:

• Pre-existing medical condition/illnesses which would impact taking part in the study The explicit exceptions to this were controlled (medicated) arthritis, asthma, hay fever, high cholesterol and reflux-related conditions. Other, unforeseen, exceptions were considered on a case-by-case basis; i.e. participants may have progressed to screening if they had a condition/illness which would not interact with the active treatments or impede performance.

• Currently taking prescription medications The explicit exceptions to this were contraceptive and hormone replacement treatments for female participants where symptoms were stable and treatment would not change during the course of the study, those medications used in the treatment of arthritis, high cholesterol and reflux-related conditions and those taken 'as needed' in the treatment of asthma and hay fever. As above, there may have been other instances of permitted medication use where no interaction with the active treatments was anticipated.

• High blood pressure (BP; systolic over 159 mm Hg or diastolic over 99 mm Hg)

• Body Mass Index (BMI) outside of the range 18.5-30 kg/m2

• Pregnant, seeking to become pregnant or lactating

• Learning and/or behavioural difficulties such as dyslexia or Attention Deficit Hyperactivity Disorder (ADHD)

• Visual impairments not corrected with glasses or contact lenses (including colour-blindness)

• Smoking (including vaping)

• Excessive caffeine intake (>500 mg per day)

• Clinically diagnosed food intolerances/sensitivities

• Antibiotic, prebiotic or probiotic (including drinks; e.g. Yakult or Actimel) use within the past 8 weeks

• Health conditions preventing fulfilment of the study requirements (this included non-diagnosed conditions for which no medication was taken)

• Inability to complete all of the study assessments

• Currently participating in other clinical or nutrition intervention studies, or had in the past 4 weeks (8 weeks if a probiotic study)

• Diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months

• Diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months

• Suffering from frequent migraines that require medication (more than or equal to 1 per month)

• Sleep disturbances (including night-shift work) and/or are taking sleep aid medication

• Any known active infections

• Does not have a bank account (required for payment)

• Are non-compliant with regards treatment consumption

Related Conditions & MeSH terms

• Cognitive Change
• Communicable Diseases
• Infections
• Microbial Colonization
• Mood Change

Intervention

Dietary Supplement:
• Turmeric Brainwave
A multiingredient herbal supplement with Turmeric as its most abundant single ingredient.

Locations

Country	Name	City	State
United Kingdom	Brain Performance and Nutrition Research Centre	Newcastle Upon Tyne	Tyne And Wear

Sponsors (2)

Lead Sponsor	Collaborator
Northumbria University	Pukka Herbs Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cognitive function (lab-based)	This outcome will be assessed via changes on the cognitive task outcomes (measured via COMPASS). COMPASS is a proprietorial software platform for delivering a range of cognitive tasks; assessing domains like memory and attention, with tasks scored for accuracy (% correct) and speed (msec).	90 days
Secondary	Cognitive function (remote)	This outcome will be assessed via changes on the cognitive task outcomes (measured via Cognimapp). Cognimapp is a proprietorial software platform for delivering a range of cognitive tasks via mobile phone; assessing domains like memory and attention, with tasks scored for accuracy (% correct) and speed (msec).	90 days
Secondary	Mood (Anxiety)	This outcome will be assessed via changes on the Generalised Anxiety Disorder 7 (GAD 7) questionnaire. This questionnaire comprises 7 items which are scored from 0 (not at all) to 3 (nearly every day) with a higher score indicating greater anxiety.	90 days
Secondary	Mood (General)	This outcome will be assessed via changes on Visual Analogue Scales (VAS). This VAS is a 100 mm line with mood related adjectives anchoring each end of the line. This is scored from mm distance along the line; with a higher score indicating greater feeling of that mood facet.	90 days
Secondary	Prospective memory	This facet of memory is assessed by the Prospective Remembering Video Procedure (PRVP) which is an 18-item list of locations and actions depicted within a 10-minute video. Participants must encode these locations and actions and recall them when watching this video at a later date.	90 days
Secondary	Delayed recall	This is a real-world recall of 10 facts, created by the principal investigator for the purposes of this study, which participants encode at the start of the trial and must recall at the end.	90 days
Secondary	Gut microbiota	This will be assessed by any shifts in gut microbial species from a stool sample collected at the start of the trial compared to the stool sample taken at the end.	90 days
Secondary	Urinary metabolome	This will be assessed by any shifts in markers identified within the urinary metabolome from a urine sample collected at the start of the trial compared to the urine sample taken at the end.	90 days